Trials / Terminated
TerminatedNCT02208063
A Phase 3 Telavancin Staphylococcus Aureus (S. Aureus) Bacteremia Trial
A Phase 3 Multicenter, Randomized, Open-label, Clinical Trial of Telavancin Versus Standard Intravenous Therapy in the Treatment of Subjects With Staphylococcus Aureus Bacteremia Including Infective Endocarditis
- Status
- Terminated
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 121 (actual)
- Sponsor
- Cumberland Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a multicenter, randomized, open-label, noninferiority trial of telavancin versus standard IV therapy control (e.g., vancomycin, daptomycin, anti-staphylococcal penicillin (PCN), or cefazolin) in the treatment of subjects with complicated Staphylococcus aureus (S. aureus) bacteremia and SA right-sided infective endocarditis (SA-RIE).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Telavancin | |
| DRUG | Vancomycin | |
| DRUG | Daptomycin | |
| DRUG | Synthetic penicillin | |
| DRUG | Cefazolin |
Timeline
- Start date
- 2014-12-01
- Primary completion
- 2018-04-12
- Completion
- 2018-04-12
- First posted
- 2014-08-04
- Last updated
- 2020-02-17
- Results posted
- 2020-02-17
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02208063. Inclusion in this directory is not an endorsement.